Published in J Neurol on August 01, 2003
A review of structural magnetic resonance neuroimaging. J Neurol Neurosurg Psychiatry (2004) 1.06
Imaging of multiple sclerosis: role in neurotherapeutics. NeuroRx (2005) 0.98
The formation of inflammatory demyelinated lesions in cerebral white matter. Ann Neurol (2014) 0.98
MR spectroscopy (MRS) and magnetisation transfer imaging (MTI), lesion load and clinical scores in early relapsing remitting multiple sclerosis: a combined cross-sectional and longitudinal study. Eur Radiol (2009) 0.94
Superparamagnetic iron oxide nanoparticles: promises for diagnosis and treatment of multiple sclerosis. ACS Chem Neurosci (2011) 0.89
Increasing normal-appearing grey and white matter magnetisation transfer ratio abnormality in early relapsing-remitting multiple sclerosis. J Neurol (2005) 0.87
Neuroradiological evaluation of demyelinating disease. Ther Adv Neurol Disord (2013) 0.80
Magnetization transfer ratio in the delayed-release dimethyl fumarate DEFINE study. J Neurol (2014) 0.80
48 echo T₂ myelin imaging of white matter in first-episode schizophrenia: evidence for aberrant myelination. Neuroimage Clin (2014) 0.76
Magnetization transfer ratio in lesions rather than normal-appearing brain relates to disability in patients with multiple sclerosis. J Neurol (2015) 0.75
The Combined Quantification and Interpretation of Multiple Quantitative Magnetic Resonance Imaging Metrics Enlightens Longitudinal Changes Compatible with Brain Repair in Relapsing-Remitting Multiple Sclerosis Patients. Front Neurol (2017) 0.75
B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med (2008) 12.90
Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med (2012) 7.58
Association between use of interferon beta and progression of disability in patients with relapsing-remitting multiple sclerosis. JAMA (2012) 5.11
Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet (2012) 4.25
Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. Lancet (2012) 3.89
Treatment effect on brain atrophy correlates with treatment effect on disability in multiple sclerosis. Ann Neurol (2014) 2.51
Longitudinal analyses of the effects of neutralizing antibodies on interferon beta-1b in relapsing-remitting multiple sclerosis. Mult Scler (2004) 2.21
Liver injury associated with the beta-interferons for MS: a comparison between the three products. Neurology (2004) 2.16
Interrupted therapy: stopping and switching of the beta-interferons prescribed for MS. Neurology (2003) 2.13
MRI parameters for prediction of multiple sclerosis diagnosis in children with acute CNS demyelination: a prospective national cohort study. Lancet Neurol (2011) 2.12
Clinical, environmental, and genetic determinants of multiple sclerosis in children with acute demyelination: a prospective national cohort study. Lancet Neurol (2011) 1.92
Induction of antigen-specific tolerance in multiple sclerosis after immunization with DNA encoding myelin basic protein in a randomized, placebo-controlled phase 1/2 trial. Arch Neurol (2007) 1.86
Is the magnetization transfer ratio a marker for myelin in multiple sclerosis? J Magn Reson Imaging (2011) 1.80
Siponimod for patients with relapsing-remitting multiple sclerosis (BOLD): an adaptive, dose-ranging, randomised, phase 2 study. Lancet Neurol (2013) 1.76
The relationship between diffuse axonal damage and fatigue in multiple sclerosis. Arch Neurol (2004) 1.76
Treatment optimization in MS: Canadian MS Working Group updated recommendations. Can J Neurol Sci (2013) 1.74
Is diffusion anisotropy an accurate monitor of myelination? Correlation of multicomponent T2 relaxation and diffusion tensor anisotropy in human brain. Magn Reson Imaging (2008) 1.70
Proposal for diagnostic criteria of tropical spastic paraparesis/HTLV-I-associated myelopathy (TSP/HAM). AIDS Res Hum Retroviruses (2006) 1.67
Magnetic resonance imaging of myelin. Neurotherapeutics (2007) 1.58
Proton magnetic resonance spectroscopic imaging can predict length of survival in patients with supratentorial gliomas. Neurosurgery (2003) 1.54
Review of automatic segmentation methods of multiple sclerosis white matter lesions on conventional magnetic resonance imaging. Med Image Anal (2012) 1.50
Natural, innate improvements in multiple sclerosis disability. Mult Scler (2012) 1.50
Myelin water imaging of multiple sclerosis at 7 T: correlations with histopathology. Neuroimage (2008) 1.47
Seeing injectable MS therapies differently: they are more similar than different. Neurology (2009) 1.47
Treatment optimization in multiple sclerosis. Can J Neurol Sci (2004) 1.44
Recommendations for clinical use of data on neutralising antibodies to interferon-beta therapy in multiple sclerosis. Lancet Neurol (2010) 1.37
Magnetic resonance frequency shifts during acute MS lesion formation. Neurology (2013) 1.35
Daclizumab HYP versus Interferon Beta-1a in Relapsing Multiple Sclerosis. N Engl J Med (2015) 1.28
Diminished Th17 (not Th1) responses underlie multiple sclerosis disease abrogation after hematopoietic stem cell transplantation. Ann Neurol (2013) 1.27
Rapid whole cerebrum myelin water imaging using a 3D GRASE sequence. Neuroimage (2012) 1.27
A prospective study of physician-observed concussion during a varsity university hockey season: white matter integrity in ice hockey players. Part 3 of 4. Neurosurg Focus (2012) 1.25
Quantitative evaluation of metal artifact reduction techniques. J Magn Reson Imaging (2004) 1.23
2010 McDonald criteria for diagnosing pediatric multiple sclerosis. Ann Neurol (2012) 1.21
Persistent organic pollutant residues in human fetal liver and placenta from Greater Montreal, Quebec: a longitudinal study from 1998 through 2006. Environ Health Perspect (2008) 1.20
Clinical efficacy of BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis: subgroup analyses of the DEFINE study. J Neurol (2013) 1.17
Lesion distribution in children with clinically isolated syndromes. Ann Neurol (2008) 1.17
Magnetization transfer ratio evolution with demyelination and remyelination in multiple sclerosis lesions. Ann Neurol (2008) 1.16
Primary progressive multiple sclerosis: part of the MS disease spectrum or separate disease entity? Acta Neuropathol (2012) 1.13
Dendritic and synaptic pathology in experimental autoimmune encephalomyelitis. Am J Pathol (2003) 1.11
Myelin water imaging: Implementation and development at 3.0T and comparison to 1.5T measurements. Magn Reson Med (2009) 1.11
Evaluation of automated techniques for the quantification of grey matter atrophy in patients with multiple sclerosis. Neuroimage (2010) 1.10
Interferon beta and long-term disability in multiple sclerosis. JAMA Neurol (2013) 1.08
1H-MRS quantification of tNA and tCr in patients with multiple sclerosis: a meta-analytic review. Brain (2005) 1.07
Automated detection of focal cortical dysplasia lesions using computational models of their MRI characteristics and texture analysis. Neuroimage (2003) 1.07
Clinically feasible MTR is sensitive to cortical demyelination in MS. Neurology (2012) 1.07
Clinical relapses of multiple sclerosis are associated with 'novel' valleys in natural killer cell functional activity. J Neuroimmunol (2003) 1.07
Diffuse axonal and tissue injury in patients with multiple sclerosis with low cerebral lesion load and no disability. Arch Neurol (2002) 1.07
Complementary information from multi-exponential T2 relaxation and diffusion tensor imaging reveals differences between multiple sclerosis lesions. Neuroimage (2007) 1.06
The role of MRI in the diagnosis of multiple sclerosis. Adv Neurol (2006) 1.05
Cancer risk in multiple sclerosis: findings from British Columbia, Canada. Brain (2012) 1.03
Validating parameters of a luciferase reporter gene assay to measure neutralizing antibodies to IFNbeta in multiple sclerosis patients. J Immunol Methods (2008) 1.03
Trimmed-likelihood estimation for focal lesions and tissue segmentation in multisequence MRI for multiple sclerosis. IEEE Trans Med Imaging (2011) 1.03
Elevated serum inflammatory markers in post-poliomyelitis syndrome. J Neurol Sci (2008) 1.03
Normal-appearing white matter in multiple sclerosis has heterogeneous, diffusely prolonged T(2). Magn Reson Med (2002) 1.02
Hematopoietic stem cell transplantation for multiple sclerosis: collaboration of the CIBMTR and EBMT to facilitate international clinical studies. Biol Blood Marrow Transplant (2010) 1.02
Reproducibility of myelin water fraction analysis: a comparison of region of interest and voxel-based analysis methods. Magn Reson Imaging (2009) 1.01
Bilirubin possesses powerful immunomodulatory activity and suppresses experimental autoimmune encephalomyelitis. J Immunol (2008) 1.01
Cause of death in MS: long-term follow-up of a randomised cohort, 21 years after the start of the pivotal IFNβ-1b study. BMJ Open (2012) 1.00
Magnetic resonance techniques for the in vivo assessment of multiple sclerosis pathology: consensus report of the white matter study group. J Magn Reson Imaging (2005) 0.99
Reappraisal of Lhermitte's sign in multiple sclerosis. Mult Scler (2005) 0.99
The role of edema and demyelination in chronic T1 black holes: a quantitative magnetization transfer study. J Magn Reson Imaging (2005) 0.99
The effect of varying echo spacing within a multiecho acquisition: better characterization of long T2 components. Magn Reson Imaging (2007) 0.98
Computational models of MRI characteristics of focal cortical dysplasia improve lesion detection. Neuroimage (2002) 0.97
Entorhinal cortex MRI assessment in temporal, extratemporal, and idiopathic generalized epilepsy. Epilepsia (2003) 0.97
Quality of life outcomes with BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis: the DEFINE study. Mult Scler (2013) 0.96
Neurodegeneration and neuroprotection in multiple sclerosis and other neurodegenerative diseases. J Neuroimmunol (2006) 0.96
Evaluating intensity normalization on MRIs of human brain with multiple sclerosis. Med Image Anal (2010) 0.96
Deep 3D Convolutional Encoder Networks With Shortcuts for Multiscale Feature Integration Applied to Multiple Sclerosis Lesion Segmentation. IEEE Trans Med Imaging (2016) 0.96
Long-term persistence with the immunomodulatory drugs for multiple sclerosis: a retrospective database study. Clin Ther (2012) 0.96
Long T2 water in multiple sclerosis: what else can we learn from multi-echo T2 relaxation? J Neurol (2007) 0.95
MR evidence of long T2 water in pathological white matter. J Magn Reson Imaging (2007) 0.93
Automated quality control of brain MR images. J Magn Reson Imaging (2008) 0.92
Gradient distortions in MRI: characterizing and correcting for their effects on SIENA-generated measures of brain volume change. Neuroimage (2009) 0.92
Interferon beta promotes nerve growth factor secretion early in the course of multiple sclerosis. Arch Neurol (2005) 0.91
Oligoclonal bands and cerebrospinal fluid markers in multiple sclerosis: associations with disease course and progression. Mult Scler (2012) 0.91
Measuring demyelination and remyelination in acute multiple sclerosis lesion voxels. Arch Neurol (2009) 0.91
Neuromyelitis optica in patients with myasthenia gravis who underwent thymectomy. Arch Neurol (2006) 0.91
Effect of peginterferon beta-1a on MRI measures and achieving no evidence of disease activity: results from a randomized controlled trial in relapsing-remitting multiple sclerosis. BMC Neurol (2014) 0.91
Rapid improvement in cortical neuronal integrity in amyotrophic lateral sclerosis detected by proton magnetic resonance spectroscopic imaging. J Neurol (2006) 0.91
Jacobian integration method increases the statistical power to measure gray matter atrophy in multiple sclerosis. Neuroimage Clin (2013) 0.91
Umbilical cord blood levels of perfluoroalkyl acids and polybrominated flame retardants. Int J Hyg Environ Health (2012) 0.90
Automatic detection of gadolinium-enhancing multiple sclerosis lesions in brain MRI using conditional random fields. IEEE Trans Med Imaging (2012) 0.90